Concomitant Genetic Alterations are Associated with Worse Clinical Outcome in EGFR Mutant NSCLC Patients Treated with Tyrosine Kinase Inhibitors

Ítems similars

• Metachronous Brain Metastasis in patients with EGFR-mutant NSCLC indicates a worse prognosis
  per: Ouyang, Wen, et al.
  Publicat: (2020)
• The Presence of Concomitant Mutations Affects the Activity of EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Patients
  per: Rachiglio, Anna Maria, et al.
  Publicat: (2019)
• Small Cell Transformation of EGFR-Mutant NSCLC Treated with Tyrosine Kinase Inhibition
  per: Adam Rock, et al.
  Publicat: (2025-10-01)
• Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors()
  per: Nishino, Mizuki, et al.
  Publicat: (2012)
• Intratumoral heterogeneity in EGFR mutant NSCLC results in divergent resistance mechanisms in response to EGFR tyrosine kinase inhibition
  per: Soucheray, Margaret, et al.
  Publicat: (2015)